Suppr超能文献

国际急性淋巴细胞白血病/淋巴瘤分类共识。

International Consensus Classification of acute lymphoblastic leukemia/lymphoma.

机构信息

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Department of Pathology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.

出版信息

Virchows Arch. 2023 Jan;482(1):11-26. doi: 10.1007/s00428-022-03448-8. Epub 2022 Nov 24.

Abstract

The updated International Consensus Classification (ICC) of B-acute lymphoblastic leukemia (B-ALL) and T-acute lymphoblastic leukemia (T-ALL) includes both revisions to subtypes previously outlined in the 2016 WHO classification and several newly described entities. The ICC classification incorporates recent clinical, cytogenetic, and molecular data, with a particular emphasis on whole transcriptome analysis and gene expression (GEX) clustering studies. B-ALL classification is modified to further subclassify BCR::ABL1-positive B-ALL and hypodiploid B-ALL. Additionally, nine new categories of B-ALL are defined, including seven that contain distinguishing gene rearrangements, as well as two new categories that are characterized by a specific single gene mutation. Four provisional entities are also included in the updated B-ALL classification, although definitive identification of these subtypes requires GEX studies. T-ALL classification is also updated to incorporate BCL11B-activating rearrangements into early T-precursor (ETP) ALL taxonomy. Additionally, eight new provisional entities are added to the T-ALL subclassification. The clinical implications of the new entities are discussed, as are practical approaches to the use of different technologies in diagnosis. The enhanced specificity of the new classification will allow for improved risk stratification and optimized treatment plans for patients with ALL.

摘要

更新后的 B 急性淋巴细胞白血病 (B-ALL) 和 T 急性淋巴细胞白血病 (T-ALL) 的国际共识分类 (ICC) 包括对 2016 年世界卫生组织分类中先前概述的亚型的修订以及几个新描述的实体。ICC 分类纳入了最近的临床、细胞遗传学和分子数据,特别强调了全转录组分析和基因表达 (GEX) 聚类研究。B-ALL 分类进行了修改,以进一步细分 BCR::ABL1 阳性 B-ALL 和低倍体 B-ALL。此外,定义了九个新的 B-ALL 类别,其中包括七个包含有区别的基因重排的类别,以及两个以特定单个基因突变为特征的新类别。四个暂定实体也被纳入更新后的 B-ALL 分类中,尽管这些亚型的明确鉴定需要 GEX 研究。T-ALL 分类也进行了更新,将 BCL11B 激活重排纳入早期 T 前体 (ETP) ALL 分类学中。此外,T-ALL 亚分类中还增加了八个新的暂定实体。讨论了新实体的临床意义,以及在诊断中使用不同技术的实用方法。新分类的增强特异性将允许对 ALL 患者进行更好的风险分层和优化治疗计划。

相似文献

1
International Consensus Classification of acute lymphoblastic leukemia/lymphoma.
Virchows Arch. 2023 Jan;482(1):11-26. doi: 10.1007/s00428-022-03448-8. Epub 2022 Nov 24.
2
Emerging molecular subtypes and therapies in acute lymphoblastic leukemia.
Semin Diagn Pathol. 2023 May;40(3):202-215. doi: 10.1053/j.semdp.2023.04.003. Epub 2023 Apr 9.
4
CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.
Haematologica. 2019 Apr;104(4):749-755. doi: 10.3324/haematol.2018.205252. Epub 2018 Oct 25.
5
Updates on lymphoblastic leukemia/lymphoma classification and minimal/measurable residual disease analysis.
Semin Diagn Pathol. 2023 Nov;40(6):457-471. doi: 10.1053/j.semdp.2023.10.001. Epub 2023 Nov 4.
6
[Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Beijing Da Xue Xue Bao Yi Xue Ban. 2013 Apr 18;45(2):327-32.
10
Early T-Cell Precursor Leukemia: A High-Risk Subtype of Acute Lymphoblastic Leukemia, Single Center Experience in Jordan.
Clin Lymphoma Myeloma Leuk. 2023 Nov;23(11):e411-e419. doi: 10.1016/j.clml.2023.08.007. Epub 2023 Sep 6.

引用本文的文献

1
Comparison of the World Health Organisation and International Consensus Classification of haematolymphoid tumours.
J Coll Med S Afr. 2024 Sep 4;2(1):75. doi: 10.4102/jcmsa.v2i1.75. eCollection 2024.
3
The miRNA Landscape of Leukemia - Cellular Actions to Therapy through Molecular Mechanisms.
Cell Biochem Biophys. 2025 Jul 18. doi: 10.1007/s12013-025-01820-4.
6
PAX Family, Master Regulator in Cancer.
Diagnostics (Basel). 2025 Jun 3;15(11):1420. doi: 10.3390/diagnostics15111420.
8
Error Reduction in Leukemia Machine Learning Classification With Conformal Prediction.
JCO Clin Cancer Inform. 2025 May;9:e2400324. doi: 10.1200/CCI-24-00324. Epub 2025 May 28.
9
Safety evaluation of inotuzumab ozogamicin: a pharmacovigilance study based on the FAERS database.
Int J Surg. 2025 Jun 1;111(6):4094-4102. doi: 10.1097/JS9.0000000000002435. Epub 2025 May 12.

本文引用的文献

1
ALLSorts: an RNA-Seq subtype classifier for B-cell acute lymphoblastic leukemia.
Blood Adv. 2022 Jul 26;6(14):4093-4097. doi: 10.1182/bloodadvances.2021005894.
6
Two novel cases of NUTM1-rearranged B-cell acute lymphoblastic leukaemia presenting with high-risk features.
Br J Haematol. 2022 Mar;196(6):1407-1411. doi: 10.1111/bjh.17995. Epub 2021 Dec 12.
8
A novel class of ZNF384 aberrations in acute leukemia.
Blood Adv. 2021 Nov 9;5(21):4393-4397. doi: 10.1182/bloodadvances.2021005318.
9
Biologic and Therapeutic Implications of Genomic Alterations in Acute Lymphoblastic Leukemia.
J Clin Med. 2021 Aug 25;10(17):3792. doi: 10.3390/jcm10173792.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验